Modern Lipid Management: A Literature Review

Pro-protein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are relatively new, non-statin, lipid-lowering drugs that reduce low-density lipoprotein cholesterol (LDL-C) by 60%. PCSK9 inhibitors reduce the blood concentrations of cholesterol by the degradation of LDL receptors, which subsequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Jahanzeb, Shabeer, Hassan, Ishaq, Uzma, Chauhan, Humaira, Akhtar, Hina Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444996/
https://www.ncbi.nlm.nih.gov/pubmed/32850243
http://dx.doi.org/10.7759/cureus.9375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444996/
https://www.ncbi.nlm.nih.gov/pubmed/32850243
http://dx.doi.org/10.7759/cureus.9375

Ejemplares similares